Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Overview E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Companies Involved in Therapeutics Development Adamed Sp z oo Astex Pharmaceuticals Inc Bristol-Myers Squibb Co Novartis AG Noxopharm Ltd Takeda Pharmaceutical Co Ltd E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Drug Profiles ADO-532 - Drug Profile Product Description Mechanism Of Action R&D Progress ASTX-660 - Drug Profile Product Description Mechanism Of Action R&D Progress AT-406 - Drug Profile Product Description Mechanism Of Action R&D Progress E-34164 - Drug Profile Product Description Mechanism Of Action R&D Progress FL-118 - Drug Profile Product Description Mechanism Of Action R&D Progress idronoxil - Drug Profile Product Description Mechanism Of Action R&D Progress LCL-161 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit XIAP for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides to Inhibit XIAP for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress T-3256336 - Drug Profile Product Description Mechanism Of Action R&D Progress E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Dormant Products E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Discontinued Products E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Product Development Milestones Featured News & Press Releases Dec 21, 2017: End Of Year Guidance On NOX66 Clinical Development Strategy For 2018 Nov 20, 2017: Noxopharm: Promising Interim Clinical Data For NOX66 Nov 16, 2017: First Patient Treated in Lupin Study at St Vincent’S Hospital, Sydney Nov 06, 2017: Debiopharm International Announces Dosing of First Patient in a Combination Trial of Debio 1143 and Avelumab in Patients with Solid Tumors including Non-Small Cell Lung Cancer (NSCLC) Oct 30, 2017: Noxopharm: Appendix 4C - Sept 2017 Quarter Sep 27, 2017: Australian NOX66 - Radiotherapy Study Opens Sep 12, 2017: Noxopharm: Positive clinical outcomes for NOX66 reported at ESMO conference Jul 06, 2017: Noxopharm provides update on NOX66 Clinical Trial Program Jun 19, 2017: Idronoxil Data Provides Hope To Treat Secondary Brain Cancers Jun 15, 2017: Debiopharm International Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN English Jun 05, 2017: Nox66 Confirmed Non-toxic Trial Cleared for Full Enrolment May 30, 2017: Noxopharm: Release Of New Corporate Presentation May 29, 2017: St Vincents Hospital Sydney Cancer Study To Commence With Nox66 Radiotherapy May 24, 2017: Noxopharm Makes Strategic Commitment To Treatment Of Rare Cancers Apr 10, 2017: Noxopharm Files Patent Application on ‘Smart’-Idronoxil Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indications, H1 2018 Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 (Contd..1), H1 2018 Products under Development by Companies, H1 2018 (Contd..2), H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Adamed Sp z oo, H1 2018 Pipeline by Astex Pharmaceuticals Inc, H1 2018 Pipeline by Bristol-Myers Squibb Co, H1 2018 Pipeline by Novartis AG, H1 2018 Pipeline by Noxopharm Ltd, H1 2018 Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018 Dormant Products, H1 2018 Dormant Products, H1 2018 (Contd..1), H1 2018 Dormant Products, H1 2018 (Contd..2), H1 2018 Discontinued Products, H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

Adamed Sp z oo Astex Pharmaceuticals Inc Bristol-Myers Squibb Co Novartis AG Noxopharm Ltd Takeda Pharmaceutical Co Ltd